Search the Newsreel

Riot Platforms (RIOT) Nears Q2 Earnings, Is The Stock 30% Undervalued?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Riot Platforms Q2 2026 earnings snapshot Riot Platforms (RIOT) reported second quarter 2026 results …

Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview

Fortress Biotech Inc (FBIO) is expected to report a loss of 20 cents per share in its upcoming earnings. This article is a preview of the company's financial performance.

Legend Biotech (LEGN) CEO Shift: Will CARVYKTI Leadership Rebalance Risk Between Pipeline and Commercial Focus?

Legend Biotech recently announced a leadership change, with CEO Ying Huang stepping down and Alan Bash, President of the CARVYKTI Business Unit, appointed as Interim CEO. This shift places an executive closely associated with the flagship CARVYKTI franchise at the helm, potentially rebalancing the …

Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026)

Veraxa Biotech Holding AG (NASDAQ: VRXA) announced the effectiveness of its F-1 filing with the SEC, dated August 6, 2026, at 4:00 P.M. The filing indicates a neutral impact and sentiment, as analyzed by StockTitan's AI. This notice of effectiveness relates to the company's …

Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline?

Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to release a quarterly update today. This update is expected to provide clarity on the company's program focus, funding discipline, the quality of current demand, and its ability to translate operating priorities into sustainable performance. The article emphasizes that …

The Technical Signals Behind (FBIOP) That Institutions Follow

This article analyzes the technical signals for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), indicating a strong near-term sentiment that could lead to a long-term positive bias. It highlights a significant risk-reward setup targeting a 12.4% gain with …

Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current …

Edesa Biotech (EDSA) to Post Earnings on Monday

Edesa Biotech (EDSA) is scheduled to release its quarterly earnings after market close on Monday, August 10th, with analysts anticipating a loss of $0.435 per share. The company previously missed estimates with a loss of $0.49 per share. Despite mixed analyst opinions, MarketBeat reports …

Price to sales forward of Burning Rock Biotech Ltd. Sponsored ADR – FWB:6BU0

This article provides financial information for Burning Rock Biotech Ltd. Sponsored ADR (FWB:6BU0) on TradingView. It specifies the "Price to sales forward" metric for the company, indicating the data was made by humans. The content primarily focuses on navigation and platform features rather than …

Cheviot Company Standalone June 2026 Net Sales at Rs 170.55 crore, up 42.46% Y-o-Y

XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for XBiotech Inc (XBIT), focusing on future EPS and revenue growth estimates. As of August 9, 2026, the company's stock is trading at 2.275 USD, with a market cap of 69.36M. The forecast section includes details on EPS, …

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 130th out of 156 companies in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with a range from $2.00 to $7.00. The company's next …

Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Riot Platforms (RIOT) Earnings Date and Reports 2026 $RIOT

Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst

Brookline Capital Markets has increased its Q3 2026 EPS forecast for SAB Biotherapeutics, projecting a narrower loss of $0.24 per share, up from $0.25. The firm also anticipates future profitability for the company, with an estimated $0.48 EPS by FY2029. Despite varying analyst sentiments, …

HC Wainwright Analysts Boost Earnings Estimates for ARQT

What is HC Wainwright's Estimate for SABS Q3 Earnings?

What is HC Wainwright's Forecast for IOVA Q3 Earnings?

VAC Q2 Deep Dive: Commercial Strategy and Owner Engagement Drive Margin Expansion

VAC Q2 Deep Dive: Commercial Strategy and Owner Engagement Drive Margin Expansion Vacation ownership company Marriott Vacations (NYSE:VAC) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 5.9% year on year to $1.32 billion. Its non-GAAP profit of $2.31 per …

Hong Kong Stock Market Movement | GenScript Biotech Corporation (01548.HK) Rises Over 8% as AIDD Boosts Demand for Experimental Validation; Institutions Bullish on Strengthened 'Shovel Seller' Thesis

Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?

Riot Announces New Date for Second Quarter 2026 Earnings Conference Call

CASTLE ROCK, Colo., Aug. 09, 2026 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), a leader in vertically integrated digital infrastructure specializing in the development of large-scale data centers and Bitcoin mining applications, announced today that it has rescheduled the …

Riot Platforms Reschedules Q2 Earnings Call for Aug. 10

Riot Platforms (NASDAQ: RIOT) has rescheduled its second-quarter 2026 earnings conference call to Monday, August 10, 2026, at 4:30 P.M. EST. Investors can access the call via webcast by registering through a provided link, or by phone using U.S. toll-free number +1 (800) 715-9871 …

Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Iovance Biotherapeutics, Inc. recently reported its latest quarterly results, surpassing analyst revenue and earnings estimates. This positive performance has led analysts to revise their forecasts upwards, suggesting increased optimism about the company's future earnings potential. The market reacted positively, with the stock price climbing …

Marriott Vacations Worldwide (VAC) Is Up 26.6% After Boosting 2026 Sales Outlook And Adding AI-Focused Strategist - What's Changed

Barinthus Biotherapeutics plc Revenue Breakdown – NASDAQ:BRNS

Marriott Vacations Worldwide Q2 Earnings Call Highlights

Marriott Vacations Worldwide (VAC) reported strong second-quarter results, exceeding guidance for contract sales and adjusted EBITDA due to increased sales productivity and owner engagement. The company's new commercial strategy, including the "Connections" program and data-driven tour logistics, significantly boosted sales and average transaction sizes. …

Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)

Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance

Adaptive Biotechnologies (ADPT) Is Up 10.5% After Raising 2026 MRD Revenue Guidance Has The Bull Case Changed?

Sana Biotechnology faces earnings test as CAR-T program advances

Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem …

Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT

Renaissance Technologies LLC has acquired 239,800 shares of Adaptive Biotechnologies Corporation, valued at approximately $3.33 million, marking a new stake in the company. Institutional investors collectively hold 99.17% of Adaptive Biotechnologies. The company reported better-than-expected quarterly revenue but missed earnings estimates, while analysts maintain …

Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates

ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds

Bronstein, Gewirtz & Grossman, LLC reminds investors of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) that a class action lawsuit has been filed against the company and its officers. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and the likelihood of FDA approval …

PharmaCyte Biotech Inc (PMCB) Stock News Today

This article provides current stock information for PharmaCyte Biotech Inc (PMCB), including its latest stock price, daily change, market cap, and links to financial data, analyst ratings, and news. As of the report, PMCB closed at $0.553 with a 1.37% increase, and indicated that …